Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment. Take 2 mins to learn more.

News & Insights

Caristo Diagnostics webinar hosted by OIC

Learn more about portfolio company Caristo Diagnostics in this webinar held in June 2020.

The webinar features a 20-minute presentation showcasing the Company and recent exciting regulatory developments in the United States, as well as touching on the Company’s efforts supporting the fight against COVID-19. The presentation is followed by a 10-minute Q&A session with Academic Founder Prof Charalambos Antoniades and CEO Dr Cheerag Shirodaria.

Caristo Diagnostics is a medical imaging company spun out from the University of Oxford’s Department of Cardiovascular Medicine in June 2018 to commercialise a novel imaging biomarker for the risk assessment and prediction of cardiovascular disease (CVD) using CT scans of the heart. In clinical studies, this novel biomarker (the Fat Attenuation Index or FAI™) has shown to be accurate in predicting heart attacks and cardiac mortality, including in patients deemed low risk by current diagnostic methods.

Important notice: This webinar recording is for information purposes only. Reliance on the information in this webinar recording, for the purpose of engaging in any investment activity, may expose an individual to a risk of losing all of the funds invested. The information disclosed in this webinar recording does not constitute, or should be considered as, an offer to buy or sell or solicitation of an offer to buy or sell any security or share.